Skip to content
Screener

Arrowhead Research ARWR Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$117.52M-194%
ALN
Alnylam PharmaceuticalsALNY
$157.25M+368%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$9.41M-6.2%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$169.6M+791%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$96.5M+11.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$121.47M-5.5%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.38B+420%
Enterprise value$12.3B+421%
P/S19.9×+15.7×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Net (loss) income including noncontrolling interest$(137,572)$367,863$(109,328)$192,645
Other comprehensive (loss) income, net of tax:
Unrealized (losses) gains on available-for-sale securities(6,934)653(6,788)146
Foreign currency translation adjustments990(400)1,100(506)
Total other comprehensive (loss) income(5,944)253(5,688)(360)
Comprehensive (loss) income(143,516)368,116(115,016)192,285
Comprehensive loss attributable to noncontrolling interest(4,425)(2,582)(6,966)(4,715)
Comprehensive (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(139,091)$370,698$(108,050)$197,000

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent?
Arrowhead Research (ARWR) reported comprehensive income (loss), net of tax, attributable to parent of -$139.09M in Q1 2026.
How has Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent decreased by 137.5% year-over-year, from $370.7M to -$139.09M.

Ask your AI about Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude